Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daicel Corporation (4202.T)
Osaka, JP
Daicel Corporation, a Japanese enterprise founded in Osaka in 1919, conducts its business operations across Japan, Asia, North America, and Europe. The company is a key producer and distributor of a broad array of products, including cellulosic derivatives, organic chemicals, diverse plastics, and pyrotechnic devices. Its extensive activities are organized into distinct segments: Medical/Healthcare, Smart, Safety, Materials, Engineering Plastics, and other specialized areas. In the Medical/Healthcare sector, Daicel supplies various cosmetic components such as 1,3-Butylene glycol, polyglycerin, and thickeners, in addition to natural health food ingredients and dietary supplements. For the pharmaceutical industry, it provides specialized chiral and achiral columns, a variety of chiral and bio reagents, and DNA/RNA-based probes, supported by comprehensive analytical, purification, synthesis, formulation, and specialized analytical tool services. The "Smart" segment focuses on advanced materials for the electronics industry, offering triacetylcellulose and films for display technologies, solvents for electronic applications, polymers for resist processes, and cleaning agents for semiconductors. Moreover, Daicel contributes to visualization technologies with its optical components, lens units, silver nanoparticle inks, and organic semiconductor devices. Within the Safety domain, the company manufactures inflators for vehicle airbags and pyro-fuses, alongside safety mechanisms for non-automotive products. Daicel is also a significant supplier of foundational chemicals and raw materials, including acetic acid and its derivatives, cellulose acetate, and acetate tow for resins, inks, and paint solvents. It further develops specialty chemicals such as cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines, which are vital for electrical materials and coatings. For the Engineering Plastics segment, Daicel delivers a wide selection of plastic solutions, encompassing engineering plastics, plastic compound products, functional sheets, molded trays, and packaging films. Beyond these core offerings, the company also produces water treatment systems and diffusers tailored for diverse industrial requirements. Daicel's comprehensive portfolio plays a crucial role in various sectors, including transportation, electronics, medical care, personal care, daily life, and environmental and energy applications. The company, which was initially named Daicel Chemical Industries, Ltd., officially adopted its current name, Daicel Corporation, in October 2011.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25% | -5.05% | -5.81% | -26.16% | -6.07% | -16.27% | -3.74% | +4.23% | +35.94% | -15.55% | +241.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 4 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-1.2% Q1'26: +0.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-78.7% Q1'26: -569.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+4.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+7.3% Q1'26: +6.2% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.2% Q1'26: +6.4% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-3.7% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×3.56× Q1'26: 3.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 7 EPS Ana. |
Mar 2027 6 Rev. Ana. 7 EPS Ana. |
Mar 2028 7 Rev. Ana. 7 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
443.78B
est: 445.76B (-0.4%)
|
449.88B
est: 454.18B (-0.9%)
|
440.06B
est: 443.37B (-0.7%)
|
462.96B
est: 466.36B (-0.7%)
|
464.86B
est: 479.00B (-3.0%)
|
412.83B
est: 414.27B (-0.3%)
|
393.57B
est: 385.63B (+2.1%)
|
467.94B
est: 460.78B (+1.6%)
|
538.03B
est: 543.02B (-0.9%)
|
558.06B
est: 572.83B (-2.6%)
|
586.53B
est: 590.90B (-0.7%)
|
577.06B
577.06B – 581.83B
-2.3% YoY
|
597.84B
597.84B – 606.85B
+3.6% YoY
|
630.42B
630.42B – 649.41B
+5.4% YoY
|
705.00B
705.00B – 721.05B
+11.8% YoY
|
750.00B
750.00B – 767.08B
+6.4% YoY
|
| EBITDA |
76.94B
est: 75.72B (+1.6%)
|
90.32B
est: 77.15B (+17.1%)
|
95.14B
est: 75.31B (+26.3%)
|
91.89B
est: 79.22B (+16.0%)
|
82.22B
est: 81.36B (+1.1%)
|
59.77B
est: 70.37B (-15.1%)
|
59.13B
est: 65.50B (-9.7%)
|
78.89B
est: 78.27B (+0.8%)
|
79.08B
est: 92.24B (-14.3%)
|
96.10B
est: 92.76B (+3.6%)
|
102.38B
est: 95.69B (+7.0%)
|
93.45B
93.45B – 94.22B
-2.3% YoY
|
96.81B
96.81B – 98.27B
+3.6% YoY
|
102.09B
102.09B – 105.17B
+5.4% YoY
|
114.17B
114.17B – 116.77B
+11.8% YoY
|
121.46B
121.46B – 124.22B
+6.4% YoY
|
| EBIT |
51.30B
est: 47.48B (+8.1%)
|
64.35B
est: 48.37B (+33.0%)
|
64.31B
est: 47.22B (+36.2%)
|
58.93B
est: 49.67B (+18.6%)
|
49.87B
est: 51.02B (-2.2%)
|
29.65B
est: 44.12B (-32.8%)
|
32.81B
est: 41.07B (-20.1%)
|
50.70B
est: 49.08B (+3.3%)
|
47.51B
est: 57.84B (-17.9%)
|
62.39B
est: 55.57B (+12.3%)
|
61.01B
est: 57.32B (+6.4%)
|
55.98B
55.98B – 56.44B
-2.3% YoY
|
58.00B
58.00B – 58.87B
+3.6% YoY
|
61.16B
61.16B – 63.00B
+5.4% YoY
|
68.39B
68.39B – 69.95B
+11.8% YoY
|
72.76B
72.76B – 74.41B
+6.4% YoY
|
| Net Income |
31.25B
est: 24.63B (+26.9%)
|
40.31B
est: 32.20B (+25.2%)
|
43.20B
est: 30.97B (+39.5%)
|
37.06B
est: 29.52B (+25.6%)
|
35.30B
est: 32.27B (+9.4%)
|
4.98B
est: 6.26B (-20.4%)
|
19.71B
est: 16.05B (+22.9%)
|
31.25B
est: 28.22B (+10.7%)
|
40.68B
est: 35.34B (+15.1%)
|
55.84B
est: 54.29B (+2.9%)
|
49.48B
est: 53.03B (-6.7%)
|
27.99B
27.58B – 28.40B
-47.2% YoY
|
42.26B
42.26B – 48.34B
+51.0% YoY
|
49.15B
48.44B – 49.87B
+16.3% YoY
|
59.41B
58.54B – 60.27B
+20.9% YoY
|
66.48B
66.48B – 68.44B
+11.9% YoY
|
| SGA |
51.31B
est: 67.40B (-23.9%)
|
54.84B
est: 68.68B (-20.1%)
|
56.41B
est: 67.04B (-15.9%)
|
60.25B
est: 70.52B (-14.6%)
|
62.91B
est: 72.43B (-13.1%)
|
61.08B
est: 62.64B (-2.5%)
|
61.14B
est: 58.31B (+4.9%)
|
68.24B
est: 69.68B (-2.1%)
|
77.66B
est: 82.11B (-5.4%)
|
74.60B
est: 84.57B (-11.8%)
|
78.90B
est: 87.24B (-9.6%)
|
85.19B
85.19B – 85.90B
-2.3% YoY
|
88.26B
88.26B – 89.59B
+3.6% YoY
|
93.07B
93.07B – 95.87B
+5.4% YoY
|
104.08B
104.08B – 106.45B
+11.8% YoY
|
110.73B
110.73B – 113.25B
+6.4% YoY
|
| EPS |
88.95
est: 90.33 (-1.5%)
|
115.02
est: 118.06 (-2.6%)
|
124.61
est: 113.56 (+9.7%)
|
107.81
est: 108.23 (-0.4%)
|
105.38
est: 118.34 (-11.0%)
|
15.49
est: 22.94 (-32.5%)
|
65.18
est: 58.84 (+10.8%)
|
104.14
est: 103.49 (+0.6%)
|
138.87
est: 129.59 (+7.2%)
|
197.56
est: 203.59 (-3.0%)
|
181.44
est: 198.87 (-8.8%)
|
104.97
104.97 – 108.08
-47.2% YoY
|
160.82
160.82 – 183.99
+53.2% YoY
|
184.35
184.35 – 189.81
+14.6% YoY
|
222.80
222.80 – 229.40
+20.9% YoY
|
253.00
253.00 – 260.49
+13.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Cambria Foreign Shareholder Yield ETF FYLD | 1.02% | 6.77M | 0.59% |
| 2 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.34% | 1.30M | 0.58% |
| 3 | Avantis International Small Cap Value ETF AVDV | 0.23% | 43.23M | 0.36% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.14% | 352.6K | 0.50% |
| 5 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.13% | 749.6K | 0.58% |
| 6 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.13% | 562.3K | 0.48% |
| 7 | WisdomTree International SmallCap Dividend Fund DLS | 0.13% | 1.35M | 0.58% |
| 8 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.12% | 810.7K | 0.41% |
| 9 | iShares International Equity Factor ETF INTF | 0.12% | 4.10M | 0.16% |
| 10 | Schwab Fundamental International Small Company Index ETF FNDC | 0.11% | 3.28M | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yasuhiro Sakaki | President, Chief Executive Officer & Director | 121M | male |
| Yoshimi Ogawa | Executive Board Chairman | 100M | male |
| Seiji Yamakado | Executive Officer & Head of Customer Center | — | — |
| Kotaro Sugimoto | Senior Managing Executive Officer, Head of Corporation Support HQ & Representative Director | — | male |
| Toshio Shiwaku | Senior Managing Executive Officer & Director | — | — |
| Takashi Miyamoto | Senior Managing Executive Officer | — | — |
| Naotaka Kawaguchi | Senior Managing Executive Officer, Senior Managing Executive Officer & Director & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4202.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
